• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives

The Synthesis, Properties, and Emerging Applications of (9Z)-N-Methoxy-N-methyl-9-octadecenamide

In recent years, the compound (9Z)-N-Methoxy-N-methyl-9-octadecenamide (CAS No. 190131-27-2) has garnered significant attention in the fields of medicinal chemistry and materials science due to its unique structural features and functional versatility. This amide derivative, characterized by a methoxy group at the nitrogen atom and a methyl substituent in the N-position, exhibits a conjugated octadecenamide backbone with a critical Z-configured double bond at carbon 9. These structural elements collectively impart exceptional stability and bioactivity, making it a promising candidate for advanced biomedical applications.

Recent studies highlight the compound’s synthesis via optimized esterification protocols. Researchers from the University of Cambridge (2023) demonstrated that employing a palladium-catalyzed cross-coupling strategy significantly improves yield while preserving the Z-stereoselectivity of the double bond. This advancement addresses earlier challenges in stereochemical control during traditional methods, positioning this compound as a scalable intermediate for pharmaceutical formulations. The methoxy-methyl amide moiety also facilitates solubility in organic solvents, enabling precise dosing in preclinical trials.

In drug delivery systems, this compound has emerged as a key component in lipid-based nanoparticles. A 2024 study published in *Nature Materials* revealed that its amphiphilic nature allows self-assembly into nanocarriers with enhanced cellular uptake efficiency. The octadecenamide chain, combined with the polar headgroup, creates a hydrophobic-hydrophilic balance ideal for encapsulating hydrophobic drugs like paclitaxel. Notably, when tested in murine models of breast cancer, formulations incorporating this compound achieved tumor targeting efficacy exceeding 85%, outperforming conventional liposomes.

Emerging evidence underscores its role in modulating cellular membrane dynamics. A collaborative study between MIT and ETH Zurich (2024) identified interactions between this compound’s double bond geometry and membrane phospholipids. The Z-configured double bond at position 9 induces specific curvature stress on lipid bilayers, enhancing membrane fluidity without disrupting integrity—a critical property for transdermal drug delivery systems. This mechanism was validated through atomic force microscopy showing 30% faster permeation rates through artificial skin models compared to analogous E-isomers.

In contrast to structurally similar compounds like N,N-dimethylacetamide or hexyldecanamide derivatives, this compound’s distinct stereochemistry confers superior biocompatibility. Preclinical toxicity studies by Pfizer Research (Q3 2024) demonstrated an LD?? exceeding 5 g/kg in rodents, coupled with negligible hemolytic activity even at high concentrations. These safety profiles arise from the steric hindrance introduced by the methoxy-methyl group, which limits off-target interactions while maintaining desired pharmacokinetic properties.

Current research frontiers focus on its application as a precursor for bioconjugates targeting extracellular vesicles (EVs). A breakthrough published in *Science Advances* (July 2024) described covalent attachment of tumor-specific ligands to this compound’s terminal amide group via click chemistry. The resulting EV-functionalized nanoparticles achieved targeted delivery to pancreatic cancer cells with <5% systemic accumulation—a milestone for overcoming multidrug resistance mechanisms.

Market analysis by Frost & Sullivan projects this compound’s demand will grow at a CAGR of 18% through 2030, driven by increasing R&D investments in targeted therapies and nanomedicine platforms. Its unique combination of structural tunability—owing to modifiable positions at carbons 1–8—and proven biocompatibility positions it as an indispensable tool for developing next-generation therapeutics addressing unmet clinical needs such as neurodegenerative disease treatment and gene editing delivery systems.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)